Copyright
©The Author(s) 2023.
World J Crit Care Med. Mar 9, 2023; 12(2): 71-88
Published online Mar 9, 2023. doi: 10.5492/wjccm.v12.i2.71
Published online Mar 9, 2023. doi: 10.5492/wjccm.v12.i2.71
Feature | CytoSorb 300[84,85,86] | Jafron HA-series (80, 130, 180, 230, 280, 330, 380)[87] | Biosky MG-Series[88] |
Manufacturer | CytoSorbents™ Inc, United States | Jafron Biomedical Co., Ltd. No. 98, Technology Sixth Road, High-tech Zone, Zhuhai City, 519085, Guangdong, China | Biosun Medical Technology Co. Ltd, China |
IFU version | October 1, 2021[87] | 11-Sep-19 | 1-Aug-18 |
Adsorbent | Crosslinked Divinylbenzene | Neutral Macroporous Resin | Medical Neutral Macroporous Synthetic Resin |
Coating | Polyvinylpyrollidone | Collodion | No data |
Adsorbent Surface | > 45000 m2 | 100000m2 | No data |
Storage fluid | Isotonic saline | Water for injection | Sterile water |
Use time/cartridge | 24 h, Can be administered up to 7 consecutive days | Depending on mode of operation: Hemoperfusion 100-250 mL/ min; Dialysis < 320 ml/ min with use upto 4 h; CRRT 150-250 mL/min with use upto 12 h; CPB up to 700 mL/ min with use upto 2.5 h | 120-180 min, Not suggested to use more than 3 times within 24 h |
Blood flow | 100-700 mL/min, Recommended > 150 mL/min | 100-700 mL/min | 100-400 mL/min; Highest rate is 250 mL/min |
Pmax | 760 mmHg | 750 mmHg | 750 mmHg |
Mode of operation covered | Hemoperfusion, Intermittent hemodialysis, CRRT, Cardiopulmonary bypass (CPB) ECMO | Hemoperfusion; Hemodialysis; CRRT; CPB | Hemoperfusion; Hemodialysis; CRRT; CPB only as comment in anticoagulation, not in setup |
Shelf life | 3 yr | 2 yr | 2 yr |
Safety report status | As of 2021: > 162000 treatments distributed without confirmed serious device related events | No data | No data |
- Citation: Mehta Y, Paul R, Ansari AS, Banerjee T, Gunaydin S, Nassiri AA, Pappalardo F, Premužić V, Sathe P, Singh V, Vela ER. Extracorporeal blood purification strategies in sepsis and septic shock: An insight into recent advancements. World J Crit Care Med 2023; 12(2): 71-88
- URL: https://www.wjgnet.com/2220-3141/full/v12/i2/71.htm
- DOI: https://dx.doi.org/10.5492/wjccm.v12.i2.71